Can regulators have a role in facilitating the development of new medicines for Parkinson's disease?
Open Access
- 6 August 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (2_suppl) , 47-54
Abstract
Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, and its prevalence has doubled in the past 25 years. New formulations of levodopa have recently been marketed that improved the ability to treat PD, but in the European Union, no new active substance for PD has been marketed since 2015, whilst two new agents have been marketed elsewhere. In spite of being the most treatable neurodegenerative disorder, several unmet medical needs still exists in PD, and efforts both from researchers, drug developers and regulators are needed to facilitate further developments in the field. There are several reasons that may account for the lack of new treatments for PD. Regulatory agencies provide scientific advice and have developed several programs to foster drug development. This manuscript discusses the main obstacles identified in the development process, the present status of approvals in European Union and the United States, and the presently available mechanisms to optimize drug development and marketing.Keywords
This publication has 15 references indexed in Scilit:
- Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE TrialEuropean Urology, 2024
- The pathogenesis of Parkinson's diseaseThe Lancet, 2024
- The therapeutic potential of psychedelics: the European regulatory perspectiveThe Lancet, 2023
- Advancing development of medicines by academia and non-profit research organizations in the European UnionNature Reviews Drug Discovery, 2020
- Levodopa Inhalation Powder: A Review in Parkinson’s DiseaseDrugs, 2020
- Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United StatesAdvances in Therapy, 2019
- Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registryParkinsonism & Related Disorders, 2017
- Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registryParkinsonism & Related Disorders, 2015
- Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payersNature Reviews Drug Discovery, 2010